4.6 Article

The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia

期刊

CANCER MEDICINE
卷 10, 期 14, 页码 4864-4873

出版社

WILEY
DOI: 10.1002/cam4.4024

关键词

clonal selection; genomics; relapse; T-ALL; teenagers and young adults

类别

资金

  1. Kay Kendall Leukaemia Fund [KKLF417]
  2. Leukaemia & Lymphoma Research
  3. European Hematology Association-EHA Partner Fellowship [2011/01]
  4. Lady Tata Memorial Trust-LTMT International Award for Research in Leukaemia
  5. Ministry of Health, INCA-Brazil
  6. Bloodwise
  7. INCA
  8. CNPq [301594/2015-5, 310877/2019-5]
  9. FAPERJ [E-26/110.712/2012, E-26/202.577/2019]
  10. Fundacao do Cancer, SwissBridge Fund
  11. Hungarian National Research, Development and Innovation Office-NKFIH [119950, 134253]
  12. New National Excellence Program of the Ministry for Innovation and Technology [UNKP-20-5-SE-22]
  13. Hungarian Academy of Sciences [BO/00320/18/5]
  14. EU's Horizon 2020 Research and Innovation Program [739593]
  15. Institute of Cancer Research
  16. Wellcome Trust [105104/Z/14/Z]
  17. Wellcome Trust [105104/Z/14/Z] Funding Source: researchfish

向作者/读者索取更多资源

The study found that adolescent and young adult T-ALL does not have specific genetic abnormalities compared to pediatric or adult T-ALL, showing a transitional genomic profile.
Background: Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T-cell acute lymphoblastic leukemia (T-ALL). Understanding the biology of disease in this age group and the genetic basis of relapse is a key goal as patients with relapsed/refractory disease have poor outcomes with conventional chemotherapy and novel molecular targets are required. This study examines the question of whether TYA T-ALL has a specific biological-molecular profile distinct from pediatric or adult T-ALL. Methods: Genomic characterization was undertaken of a retrospective discovery cohort of 80 patients aged 15-26 years with primary or relapsed T-ALL, using a combination of Genome-Wide Human SNP Array 6.0, targeted gene mutation and promoter methylation analyses. Findings were confirmed by MLPA, real-time quantitative PCR, and FISH. Whole Exome Sequencing was performed in 4 patients with matched presentation and relapse to model clonal evolution. A prevalence analysis was performed on a final data set of 1,792 individual cases to identify genetic lesions with age specific frequency patterns, including 972 pediatric (1-14 years), 439 TYA (15-24 years) and 381 adult (>= 25 years) cases. These cases were extracted from 19 publications with comparable genomic data identified through a PubMed search. Results: Genomic characterization of this large cohort of TYA T-ALL patients identified recurrent isochromosome 7q i(7q) in our discovery cohort (n = 3). Prevalence analysis did not identify any age specific genetic abnormalities. Genomic analysis of 6 pairs of matched presentation - relapsed T-ALL established that all relapses were clonally related to the initial leukemia. Whole exome sequencing analysis revealed recurrent, targetable, mutations disrupting NOTCH, PI3K/AKT/mTOR, FLT3, NRAS as well as drug metabolism pathways. Conclusions: All genetic aberrations in TYA T-ALL occurred with an incidence similar or intermediate to that reported in the pediatric and adult literature, demonstrating that overall TYA T-ALL exhibits a transitional genomic profile. Analysis of matched presentation - relapse supported the hypothesis that relapse is driven by the Darwinian evolution of sub-clones associated with drug resistance (NT5C2 and TP53 mutations) and re-iterative mutation of known key T-ALL drivers, including NOTCH1.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据